vs-6766

Small moleculeexperimental

Clinical trial activity

10 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
9
Phase 3
0
Phase 4
0

Earliest trial started Nov 30, 2020 (NCT04620330)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06682572Phase 2Oct 30, 2024Japanese Gynecologic Oncology Group, Verastem, Inc.
NCT05608252Phase 1/Phase 2 (Phase 2)Mar 31, 2023Eli Lilly, Harvard University, Verastem, Inc.
NCT05669482Phase 1/Phase 2 (Phase 2)Jan 15, 2023Verastem, Inc.
NCT05512208Phase 2Dec 31, 2022University of Oklahoma, Verastem, Inc.
NCT05200442Phase 1/Phase 2 (Phase 2)Aug 22, 2022University of Chicago, Verastem, Inc.
NCT05074810Phase 1/Phase 2 (Phase 2)Dec 31, 2021Amgen, Verastem, Inc.
NCT05187169Phase 1Dec 16, 2021Verastem, Inc.
NCT04720417Phase 2Jan 26, 2021Thomas Jefferson University, Verastem, Inc.
NCT04625270Phase 2Dec 21, 2020European Network for Gynaecological Oncological Trial, GOG Foundation, Inc., Gynecologic Oncology Group, Verastem, Inc.
NCT04620330Phase 2Nov 30, 2020University of Colorado, Denver, Verastem, Inc.
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Verastem, Inc.For profit10622020
AmgenFor profit1012021
Eli LillyFor profit1012023
European Network for Gynaecological Oncological TrialAcademic/Hospital1012020
GOG Foundation, Inc.Academic/Hospital1012020
Gynecologic Oncology GroupAcademic/Hospital1012020
Harvard UniversityAcademic/Hospital1112023
Japanese Gynecologic Oncology GroupAcademic/Hospital1012024
Thomas Jefferson UniversityAcademic/Hospital1112021
University of ChicagoAcademic/Hospital1112022
University of Colorado, DenverAcademic/Hospital1012020
University of OklahomaAcademic/Hospital1112022
12 organizations
Page 1 / 1